AKEDA PHARMACEUTICAL COMPANY LIMITED;TAKEDA PHARMACEUTICAL COMPANY LIMITED
发明人:
CHEN, YOUNG,CO, ERICK WANG,GUNTUPALLI, PRASUNA,LAWSON, JOHN DAVID,NOTZ, WOLFGANG REINHARD LUDWIG,STAFFORD, JEFFREY A.,TON-NU, HUONG-THU
申请号：
ES09706850
公开号：
ES2475206T3
申请日:
2009.01.30
申请国别(地区):
ES
年份:
2014
代理人:
摘要：
Compound of formula (IV): or a tautomer, stereoisomer or pharmaceutically acceptable salt thereof, wherein X is O； R1 is -L-R45； R2 is selected from the group consisting of hydrogen and methyl； R3 is of the formula in which the C ring is selected from the group consisting of aryl (C4-6) and heteroaryl (C1-5), each unsubstituted or substituted with 1-3 substituents selected from the group consisting of halo , alkoxy, alkyl, amino, alkylamino, haloalkyl and haloalkoxy； R12 is selected from the group consisting of aryl (C4-12), heteroaryl (C1-10), bicycloaryl (C9-12), heterobicycloaryl (C4-12), cycloalkyl (C3-12) and heterocycloalkyl (C2-11), each unsubstituted or substituted with 1-3 substituents selected from group A； R4 is selected from the group consisting of hydrogen, (C1-6) alkyl, (C2-6) alkenyl, (C26) alkynyl, (C1-6) hydroxyalkyl, (C1-6) aminoalkyl, (C3-12) cycloalkyl - (C1-5) alkyl, heterocycle (C3-12) alkyl-(C1-10) alkyl, aryl (C1-10) alkyl, heteroaryl (C1-10) -alkyl (C1-5), aryl (C4-12), heteroaryl (C1-10), cycloalkyl (C3-7), cycloalkenyl (C5-7) and heterocycloalkyl (C3-12), each unsubstituted or substituted with one or more substituents selected from group A； R6 and R6 'are each independently selected from the group consisting of hydrogen, halogen and (C1-6) alkyl unsubstituted or substituted with one or more substituents selected from group A； R45 is selected from the group consisting of hydrogen, hydroxyl, halo, (C1-3) alkyl, hydroxyalkyl (C1-3), alkoxy (C1-3), amino, carbonylamino, aminocarbonyl, carbonyl, hydroxycarbonyl, aryl (C4-6 ), heteroaryl (C1-5), cycloalkyl (C3-6) and heterocycloalkyl (C3-5), each unsubstituted or substituted with one or more substituents selected from the groupCompuesto de la fórmula (IV): o un tautómero, estereoisómero o sal farmacéuticamente aceptable del mismo, en la que X es O； R1 es -L-R45； R2 se selecciona del grupo que consiste en hidrógeno y metilo； R3 es de la fórmula en la que el anillo C se selecciona del grupo que co
